Abnormal cannabidiol is a synthetic regioisomer of cannabidiol that fails to elicit either central cannabinoid (CB1) or peripheral cannabinoid (CB2) receptors responsiveness and is without psychotropic activity. It induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism. O-1821 is a cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (CB1)/peripheral cannabinoid (CB2) receptors endothelial receptor. O-1918 does not bind to CB1 or CB2 receptors at concentrations up to 30 µM and inhibits the vasorelaxant effects of abnormal cannabidiol in vitro and in whole animals. The biological activity of O-1821 has not been reported.
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1,2,4-triazole is a chemical compound that belongs to the class of triazole derivatives. It has gained significant attention in the scientific community due to its potential therapeutic and environmental applications. This paper aims to provide an overview of the synthesis, chemical structure, biological activity, and applications of 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1,2,4-triazole.
Arachidonamide, also known as anandamide, is an endogenous cannabinoid neurotransmitter that is synthesized in the brain and peripheral tissues. It is a member of the endocannabinoid system, which plays a crucial role in regulating various physiological processes, including pain, appetite, mood, and immune function. Arachidonamide is a lipid mediator that binds to cannabinoid receptors, CB1 and CB2, and exerts its effects through various signaling pathways.
N-(2-methyl-2S-hydroxy-ethyl)arachidonoylamide, also known as NADA, is a naturally occurring endocannabinoid that is synthesized in the body. It belongs to the family of N-acylethanolamines and is structurally similar to anandamide, another endocannabinoid. NADA has been found to have various biological activities and potential therapeutic applications.
S-1 Methanandamide is a synthetic analog of the endocannabinoid anandamide, which is a naturally occurring lipid mediator that binds to cannabinoid receptors in the body. S-1 Methanandamide has been extensively studied for its potential therapeutic applications in various medical conditions, including pain, inflammation, and cancer. This paper aims to provide a comprehensive review of S-1 Methanandamide, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, future perspectives, and challenges.